0P48 Moberg Pharma Ab (publ)

STOCKHOLM, Jan. 7, 2021 /PRNewswire/ -- OncoZenge AB (publ), Moberg Pharma's subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge^®, currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032.

The new patent protects sustained-release lozenge containing bupivacaine, for treatment or alleviation of pain in the oral cavity. It is a divisional of the previously granted European patent 2 701 681, that specifically protects the use of lozenges for treatment of pain due to oral mucositis for cancer patients. BupiZenge^® has previously been granted patents with a similar scope in the United States and Canada.

"The patent significantly strengthens the intellectual property for BupiZenge^® in Europe", Pirkko Tamsen, CEO of OncoZenge comments. "It protects the use of BupiZenge^® in all relevant indications for treatment of pain in the oral cavity".

About Oral Mucositis and BupiZenge^®

Globally, around 5 million people suffer from Oral mucositis ("OM") after cancer treatment. OM is an inflammation of the mucous membranes in the mouth and throat, which results in painful ulcers. OM is considered the most debilitating side effect of radiation therapy and chemotherapy and commonly occurs. After radiation therapy in the head and neck region, 90 percent of patients develop OM, and of the patients who are treated with chemotherapy around 30 percent are affected. OM causes severe pain, difficulty to swallow and talk, and can lead to interruptions in cancer treatment as well as increased health care costs.

The BupiZenge^® technology encompasses novel lozenge formulations of bupivacaine, a local anesthetic with a well-established long acting effect, currently available on the market for other indications as an injectable. In a previous phase 2 study on cancer patients, BupiZenge^® has demonstrated statistically significant pain relief in the oral cavity and throat; the pain level in the mouth was reduced by 50 percent. compared to the current treatment.

CONTACT:

For additional information, please contact:

Pirkko Tamsen
CEO OncoZenge
telephone: +46 760 09 84 99
e-mail: pirkko.tamsen@oncozenge.se

Anna Ljung
CEO Moberg Pharma
telephone: +46 707 66 60 30
e-mail: anna.ljung@mobergpharma.se

About this information

The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 a.m. CET on January 7^th, 2021.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/moberg-pharma/r/oncozenge-announces-issue-of-european-patent-related-to-bupizenge-,c3264095

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/oncozenge-announces-issue-of-european-patent-related-to-bupizenge-301202572.html

SOURCE Moberg Pharma